The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
- Registration Number
- NCT01682642
- Lead Sponsor
- AZ Jan Palfijn Gent
- Brief Summary
In this study of endometriosis patients we compare a common treatment of surgical therapy and medical treatment for 3 months (Zoladex) with patients receiving only surgical therapy. In both cases they immediately start In Vitro Fertilization (IVF) treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 120
Inclusion Criteria
- laparoscopical vaporization of endometriosis
- 1,2, 3e IVF cycle
- endometriosis stage I and II
- younger than 38 years
Exclusion Criteria
- endometriosis cysts
- uterine pathology
- endocrinological diseases and problems
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Zoladex Zoladex After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
- Primary Outcome Measures
Name Time Method Number of Metaphase II Cells (MII) 3 weeks number of MII cells retrieved
- Secondary Outcome Measures
Name Time Method Pregnancy Rate 12 weeks The number of ongoing pregnancies obtained which still is the most important issue for the patients.
Good Embryo Quality 3 days after oocyte retrieval The development of the embryo at the time of transfer on day 3. Good quality is defined by more than 7 cells and less then 20% fragmentation on day 3.
Total Follicle Stimulating Hormone (FSH) Dose 3 weeks total dose of FSH needed at the end of stimulation
Number of Cryopreserved Embryos 1 week after oocyte retrieval number of blastocytes that can be cryopreserved
Number of Pro Nuclear Cell (2PN) 1 day after oocyte retrieval number of 2PN
Trial Locations
- Locations (1)
AZ Jan Palfijn
🇧🇪Gent, Oost-vlaanderen, Belgium